RNS Number:0741K
Hikma Pharmaceuticals Plc
17 December 2007


For Immediate Release                                           17 December 2007


                 Notification of transaction by a Director/PDMR


LONDON, 17 December 2007 - Hikma Pharmaceuticals PLC (the "Company") (LSE: HIK)
(DIFX:HIK) announces that Mr. Samih Darwazah, Non-executive Chairman of the
Company, has today notified the Company of the sale of 320,000 ordinary shares
of 10 pence each in the capital of the Company, received by him pursuant to an
exercise of share options in the Company on 15 October 2007.


The sale was made in London at a price of 498.0 pence per share and was executed
on 14 December 2007. The shares sold represented 0.187% of the outstanding share
capital of the Company, and following the sale Mr Darwazah remains interested in
1,706,506 ordinary shares, representing 0.999% of the share capital of the
Company.


Mr. Darwazah is both a director and a Person Discharging Managerial
Responsibility in respect of the Company, and the above notification relates to
DTR 3.1.4R(1)(a) and other Listing Rules.


                                   -- ENDS --


Enquiries:

Hikma Pharmaceuticals PLC

Henry Knowles                                  +44 20 7399 2760

Company Secretary

Susan Ringdal                                  +44 20 7399 2760

Investor Relations Director

Brunswick Group

Jon Coles / Justine McIlroy / Alex Tweed       +44 20 7404 5959


About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: "Branded", "Injectables" and "Generics".
Hikma's operations are based principally in the Middle East and North Africa
("MENA") region, where it is a market leader and sells across 17 countries, the
United States and Europe. In 2006, the Group achieved revenues of $317 million
(2005 $262 million) and profit attributable to shareholders was $55 million
(2005 $44 million). At 30 June 2007, the Group had over 2,700 employees. For
news and other information, please visit www.hikma.com.


                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
RDSBXBDDISBGGRR
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.